Last updated: March 14, 2026
Who Filed and What Is the Case About?
The lawsuit involves Novo Nordisk, Inc., filing against Viatris Inc. in the United States District Court for the District of Delaware. Filed on January 4, 2023, the case number is 1:23-cv-00013. The dispute centers on patent infringement claims related to insulin formulations used in diabetes treatment.
Complaint Details
Novo Nordisk alleges that Viatris infringed on one or more patents protecting its insulin products. The complaint specifies violations concerning patent rights that cover formulations, delivery methods, and manufacturing processes. The plaintiff asserts that Viatris’ proposed or currently marketed insulin products directly infringe these patents.
Patent Claims
The complaint cites U.S. Patent Nos. 10,913,543 and 11,538,275, among others. These patents cover:
- Long-acting insulin formulations.
- Specific excipient compositions.
- Delivery methods enhancing patient compliance.
Allegations of Infringement
Novo Nordisk claims that Viatris introduced insulin products to the market that mirror patented formulations. The company argues this infringes on its exclusive rights, despite Viatris’ attempts to design around certain patents.
Defendant's Response
Viatris has not yet filed a formal answer or motion to dismiss at the time of this report. The company has indicated intention to contest the allegations, likely asserting non-infringement or invalidity of the patents.
Legal Proceedings and Strategy
The case remains in initial stages. An early case management conference is scheduled for March 2023. Discovery is expected to focus on the validity of the patents, scope of claims, and technical similarities between the products.
Viatris could seek to invalidate the patents through inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB). Alternatively, Viatris might argue that its formulations do not infringe or that the patents are invalid due to prior art.
Market Impact and Industry Context
This case reflects a broader trend of incumbent pharmaceutical firms defending patent rights against generic and biosimilar entrants. Litigation duration typically spans 18-36 months, with potential settlement or patent challenges influencing market share and pricing strategies.
Comparison with Similar Cases
| Case |
Patent(s) Involved |
Outcome |
Duration |
Industry Implication |
| Eli Lilly v. Amneal |
U.S. Patent No. 9,655,141 |
Settlement |
2 years |
Patent robust for complex biologics |
| Sanofi v. Biocon |
U.S. Patent No. 8,560,844 |
Invalidated |
3 years |
Patent litigation risks for biosimilars |
Forecast and Risks
- If Novo Nordisk proves patent infringement, Viatris’ product launch could face delays or modifications.
- Patent invalidity arguments may succeed if prior art is compelling.
- Both parties might pursue settlement, which could involve cross-licensing or monetary agreements.
Key Takeaways
- The case underscores patent protection's critical role in insulin market competition.
- Viatris aims to challenge patent validity or demonstrate non-infringement.
- Litigation timeline remains uncertain, pending motions and discovery.
- Outcomes could influence future patent strategies in biologic and biosimilar development.
- The case exemplifies patent enforcement risks for biosimilar entrants.
FAQs
1. How long does patent litigation typically last in the United States?
Litigation durations range from 18 to 36 months, depending on complexity and procedural steps.
2. Can Viatris’s products be marketed during the litigation?
Yes, unless the court issues an injunction, but the defendant may face patent infringement liability retroactively.
3. What are Viatris’s options if the patents are upheld?
Options include designing around the patents, challenging validity through IPR, or settling with licensing agreements.
4. How do patent invalidity defenses affect a patent infringement case?
Proving patents invalid can dismiss infringement claims, allowing generic or biosimilar products to market freely.
5. What is the significance of this case for the insulin market?
It highlights ongoing legal battles around patent rights, which influence product availability, pricing, and field innovation.
References
[1] U.S. District Court for the District of Delaware. (2023). Novo Nordisk, Inc. v. Viatris Inc. | 1:23-cv-00013. Court docket.
